Search

Polymer Factory Sweden AB (publ) Interim Report Q3 2021

The period in summary

Third quarter, July-September 2021

  • The Company signed an OEM agreement with Bruker Daltonics GmbH and Co. KG

  • The Company received an order of approximately KSEK 400 from a global biotechnology company.

  • Net sales for the period amounted to KSEK 376 (381).

  • The loss for the period amounted to KSEK -933.

Year to date, January-September 2021

  • Net sales amounted to KSEK 1,802 (1,026), an increase with 76% compared to the same period 2020.

  • The operating loss for the period amounted to KSEK -2,347 of which KSEK 691 can be derived from IPO related costs.


Key Figures

(KSEK) Jul-Sep Jul-Sep Jan-Sep Jan-Sep 2021 2020 2021 2020

Net sales 376 381 1,802 1,026

Profit (loss) for the period -933 -54 -2,532 -402

Total assets - - 12,106 3,415

Equity / assets ratio (%) - - 94 74

Cash flow for the period -3,278 -195 6,447 201

Basic earnings per share (SEK) -0.14 -0.05* -0.37 -0.40*


*Share volume 2020 is adjusted for a split 1:1000


Comments from CEO Elin Mignérus


Q3 2021 has been focused on organizational growth – from people and premises to customer projects. Interesting business projects have come in, and the company signing a long-lasting OEM agreement with Bruker Daltonics GmbH and Co. KG for SpheriCal® was a great milestone for Polymer Factory.


In Q3, we have made great progress with respect to securing new business opportunities. As reported in August, we received an order of approximately KSEK 400 from a global life science company, which will be delivered during Q4. This order includes customized materials and supports a further development of our dendritic materials portfolio. Related to this, Polymer Factory are planning for launch of a completely new product segment, BowtieD®, in Q4 – these are highly advanced dendrimers with multiple functionalities that have shown great results in previous research and as carriers for therapeutic applications. Stay tuned for more information about the launch!


Closing this quarter, we look back at an eventful three months at Polymer Factory. Apart from expanding the team with a product manager, we have achieved several key milestones for the company that will serve our growth journey; premises have been expanded through the addition of one lab facility for analytical materials, the latter hosting the MALDI-TOF mass spectrometry instrument that was installed at Polymer Factory in August. This is a powerful instrument that will support the acceleration of SpheriCal® in new and existing markets of high throughput detections.


As the team has been strengthened with a new product manager responsible for analytical materials during the period, we now have a better capacity to meet future customer requests and increase both production as well as sales and marketing activities. By growing the organization, Polymer Factory is better equipped to reach the company’s goals in the different business segments.


During this quarter, we have seen customers in different segments, with representation from academia, vaccine developers, big pharma, tests for covid-19, and more. Our portfolio of dendritic materials continues to be utilized for a range of applications, and we are constantly working to intensify and deepen the customer relationships to grow our business further. Moreover, Polymer Factory has a truly international customer base, with representation from four different continents during this quarter. To further our protection in international markets, we have during this quarter applied for extension of our trademark SpheriCal® to also be protected in the USA, Japan, South Korea, and Australia.


We are now approaching the end of 2021 and have completed most of our target milestones during our first half year as a publicly traded company. We look forward to closing this year on a positive note and to continue delivering value to all our customers and shareholders!


Find the Interim report HERE


About Polymer Factory

Polymer Factory was founded in 2006 at KTH Royal Institute of Technology and its Board of Directors have been essential in driving dendritic nanotechnology research to commercialization for almost 15 years – expertise that has been transferred to the Company’s products. Emerging from many years of cutting-edge research within the field, Polymer Factory today has, in the Company’s assessment, the world’s largest product portfolio of dendritic materials with customers ranging from Big Pharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. Polymer Factory has also used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments.


For more information, please contact: Elin Mignérus, CEO

Phone: +46 (0) 79 300 27 76

E-mail: elin.mignerus@polymerfactory.com


This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25 November 2021.


Find the full press release here:

Press release 25th November - Interim Report Q3
.pdf
Download PDF • 217KB